Biomm S.A.

São Paulo Stock Exchange BIOM3.SA

Biomm S.A. EBIT Margin for the year ending December 31, 2023: -55.71%

Biomm S.A. EBIT Margin is -55.71% for the year ending December 31, 2023, a 23.48% change year over year. EBIT ratio is the ratio of EBIT to revenue, measuring a company's operating profitability without considering non-operating income or expenses.

Biomm S.A. EBIT Margin for the year ending December 31, 2022 was -72.80%, a -19.24% change year over year.
Biomm S.A. EBIT Margin for the year ending December 31, 2021 was -61.06%, a 36.70% change year over year.
Biomm S.A. EBIT Margin for the year ending December 31, 2020 was -96.45%, a 80.01% change year over year.
Biomm S.A. EBIT Margin for the year ending December 31, 2019 was -482.39%, a 76.30% change year over year.

Key data

Date	EBIT Margin	EPS (Basic)	EPS (Diluted)	Shares (Basic, Weighted)

São Paulo Stock Exchange: BIOM3.SA

Biomm S.A.

CEO	Mr. Heraldo Carvalho Marchezini
IPO Date	Jan. 11, 2000
Location	Brazil
Headquarters	Rua dos Pinheiros, 610
Employees	130
Sector	Healthcare
Industries Pharmaceuticals 3D Printing Biotechnology Cosmetics Drugstores & Retail Pharmacies Eyewear Personal Care Pet Food

Description

Biomm S.A. operates as a biotechnology company in Brazil. It offers AFREZZA, a human insulin inhalation powder; CONFORT CARE, a moisturizing foot cream; GLARGILIN, a glargine insulin; and HERZUMA, a trastuzumab. Biomm S.A. was founded in 2001 and is based in São Paulo, Brazil.

Key trends

Past 5 years